NASDAQ:TNXP

Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

Tonix Pharmaceuticals logo
$2.38 -0.17 (-6.67%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.39 +0.01 (+0.25%)
As of 11/20/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Tonix Pharmaceuticals Stock (NASDAQ:TNXP)

Advanced

Key Stats

Today's Range
$2.30
▼
$2.63
50-Day Range
$2.38
▼
$11.76
52-Week Range
$2.30
▼
$20.56
Volume
1.26 million shs
Average Volume
1.08 million shs
Market Capitalization
$46.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.33
Consensus Rating
Buy

Company Overview

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases.

Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.

Tonix is led by co-founder, chairman and chief executive officer Seth Lederman, M.D. Its operations and commercial focus are centered in the United States.

AI Generated. May Contain Errors.

Tonix Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

TNXP MarketRank™: 
3.553684210525 of 5 stars

Tonix Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 215th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Tonix Pharmaceuticals has a consensus price target of $22.33, representing about 838.4% upside from its current price of $2.38.

  • Amount of Analyst Coverage

    Tonix Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Tonix Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($10.73) to ($6.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tonix Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tonix Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tonix Pharmaceuticals has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    19.74% of the float of Tonix Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 4.14.
  • Change versus previous month

    Short interest in Tonix Pharmaceuticals has recently increased by 12.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tonix Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Tonix Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Tonix Pharmaceuticals has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    11 people have searched for TNXP on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $47,830.00 in company stock, which represents 0.1034% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,830.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    2.00% of the stock of Tonix Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tonix Pharmaceuticals' insider trading history.
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TNXP Stock News Headlines

Whoops! I wasn’t supposed to share this with you yet
Traders have paid as much as $500 for technology like this. Thomas Wood of Base Camp Trading is offering his proprietary Snapback Indicator for just $7. There is no subscription and no recurring charge, and it's yours for life. The indicator is designed to help identify potential market turning points, showing when it may be time to buy, sell, or go short.tc pixel
See More Headlines

TNXP Stock Analysis - Frequently Asked Questions

Tonix Pharmaceuticals' stock was trading at $15.62 at the beginning of the year. Since then, TNXP stock has decreased by 84.8% and is now trading at $2.38.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Monday, November, 9th. The company reported ($2.89) earnings per share for the quarter, missing analysts' consensus estimates of ($2.39) by $0.50. The firm had revenue of $17.23 million for the quarter, compared to analysts' expectations of $16.32 million. Tonix Pharmaceuticals had a negative trailing twelve-month return on equity of 80.97% and a negative net margin of 420.45%.
Read the conference call transcript
.

Tonix Pharmaceuticals's stock reverse split before market open on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Top institutional investors of Tonix Pharmaceuticals include Logos Global Management LP (2.83%), State Street Corp (1.72%), Goldman Sachs Group Inc. (0.54%) and Ieq Capital LLC (0.36%). Insiders that own company stock include Seth Lederman, Richard Newcomb Stillwell, Carolyn E Taylor and Richard H Bagger.
View institutional ownership trends
.

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), NIO (NIO), Tesla (TSLA), Advanced Micro Devices (AMD), Ocugen (OCGN) and SNDL (SNDL).

Company Calendar

Last Earnings
11/09/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:TNXP
CIK
1430306
Employees
142
Year Founded
2007

Price Target and Rating

High Price Target
$27.00
Low Price Target
$18.00
Potential Upside/Downside
+838.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($12.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.02 million
Net Margins
-420.45%
Pretax Margin
-420.45%
Return on Equity
-80.97%
Return on Assets
-70.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.57
Quick Ratio
4.47

Sales & Book Value

Annual Sales
$43.05 million
Price / Sales
1.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.27 per share
Price / Book
0.23

Miscellaneous

Outstanding Shares
19,432,000
Free Float
19,043,000
Market Cap
$46.25 million
Optionable
Optionable
Beta
1.90

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:TNXP) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners